Search Within

Yvette J Bernal

Refine Results
Formats
  1. Meeting Abstract (14)
  2. Journal Article (6)
Groups
  1. Adult Leukemia (20)
  2. Center for Hematologic Malignancies (20)
  3. Hematologic Malignancies Research (20)
  4. Hematologic Oncology, Division of (20)
  5. Leukemia Service (20)
  6. Molecular Pharmacology and Chemistry Program Faculty (19)

More Groups

People
  1. Renier Brentjens (19)
  2. Isabelle Riviere (18)
  3. Jae Park (18)
  4. Michel Sadelain (17)
  5. Xiuyan Wang (17)
  6. Kevin Curran (12)

More People

Years
  1. 2018 (2)
  2. 2017 (2)
  3. 2015 (5)
  4. 2014 (3)
  5. 2013 (4)
  6. 2012 (2)

More Years

Publications
  1. Blood (9)
  2. Molecular Therapy (3)
  3. Journal of Clinical Oncology (2)
  4. Science Translational Medicine (2)
  5. Blood Advances (1)
  6. Cancer Discovery (1)

More Publications

Publishers
  1. American Society of Hematology (10)
  2. Nature Publishing Group (3)
  3. American Association for the Advancement of Science (2)
  4. American Society of Clinical Oncology (2)
  5. American Association for Cancer Research (1)
  6. Ferrata Storti Foundation (1)

More Publishers

Results (20)

Export to EndNote | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia
    Journal Article

    Santomasso, B. D.; Park, J. H.; Salloum, D.; Riviere, I.; Flynn, J.; Mead, E.; Halton, E.; Wang, X.; Senechal, B.; Purdon, T.; more...
    Cancer Discovery (2018)

    Fulltext@MSK | Save
  • Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia
    Journal Article

    Maslak, P. G.; Dao, T.; Bernal, Y.; Chanel, S. M.; Zhang, R.; Frattini, M.; Rosenblat, T.; Jurcic, J. G.; Brentjens, R. J.; Arcila, M. E.; more...
    Blood Advances (2018)

    Fulltext@MSK | Save
  • Development and evaluation of a human single chain variable fragment (scFv) derived BCMA targeted CAR T Cell vector leads to a high objective response rate in patients with advanced MM
    Meeting Abstract

    Smith, E. L.; Mailankody, S.; Ghosh, A.; Masakayan, R.; Staehr, M.; Purdon, T. J.; Halton, E.; Diamonte, C.; Anant, P.; Bernal, Y.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A Phase I trial of 19-28z CAR-T cells post-high dose therapy and autologous transplantation (HDT-ASCT) for relapsed and refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL)
    Meeting Abstract

    Sauter, C.; Riviere, I.; Senechal, B.; Ni, A.; Bernal, Y.; Wang, X.; Purdon, T.; Hall, M.; Moskowitz, C.; Giralt, S.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Implications of minimal residual disease negative complete remission (MRD-CR) and allogeneic stem cell transplant on safety and clinical outcome of CD19 targeted 19-28z CAR modified T cells in adult patients with relapsed, refractory B-cell ALL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X. Y.; Bernal, Y.; Purdon, T.; Halton, E.; Wang, Y.; Curran, K. J.; Sauter, C. S.; Sadelain, M.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Efficacy and safety of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed or refractory B-ALL
    Meeting Abstract

    Park, J.; Riviere, I.; Wang, X.; Bernal, Y.; Purdon, T.; Halton, E.; Curran, K.; Sauter, C.; Sadelain, M.; Brentjens, R.
    Haematologica (2015)

    Fulltext@MSK | Save
  • Phase I clinical trial of autologous CD19-targeted 19-28z CAR T cells in adult patients with Relapsed or refractory B-ALL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X. Y.; Bernal, Y.; Halton, E.; Quintanilla, H.; Curran, K.; Sauter, C.; Sadelain, M.; Brentjens, R. J.
    Molecular Therapy (2015)

    Fulltext@MSK | Save
  • Phase I trial of 19-28z chimeric antigen receptor modified T cells (19-28z CAR-T) post-high dose therapy and autologous stem cell transplant (HDT-ASCT) for relapsed and refractory (rel/ref) aggressive B-cell non-Hodgkin lymphoma (B-NHL)
    Meeting Abstract

    Sauter, C. S.; Riviere, I.; Bernal, Y.; Wang, X. Y.; Purdon, T.; Yoo, S.; Moskowitz, C. H.; Giralt, S.; Matasar, M. J.; Curran, K. J.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Efficacy and safety of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed or refractory B-ALL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X. Y.; Bernal, Y.; Purdon, T.; Halton, E.; Curran, K. J.; Sauter, C. S.; Sadelain, M.; Brentjens, R. J.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Interim safety analysis: A phase I trial of high dose therapy and autologous stem cell transplantation followed by infusion of chimeric antigen receptor modified T-cells (19-28z CAR-T) directed against CD19+B-cells for relapsed and refractory aggressive B cell non-Hodgkin lymphoma (B-NHL)
    Meeting Abstract

    Sauter, C. S.; Riviere, I.; Bernal, Y. J.; Wang, X. Y.; Purdon, T. J.; Yoo, S.; Moskowitz, C. H.; Giralt, S.; Matasar, M. J.; Curran, K. J.; more...
    Blood (2014)

    Fulltext@MSK | Save